Cytomegalovirus (CMV) Retinitis Therapeutics – Pipeline Assessment and Market Forecasts to 2017

CMV Retinitis Therapeutics Market is Forecasts to Show Negative Growth until 2017

Online PR News – 03-May-2011 – – GlobalData valued the global CMV retinitis therapeutics market at $525m in 2010, and forecasts it to decline at a negative CAGR of 3.8% to reach $400m in 2017. This predicted decline is primarily attributed to the patent expiry of the main branded product in the market. However, the impact of this patent expiry will only be seen in the last two years of the forecast. Before that, the market is expected to grow to reach $605m in 2015.

The patient population growth is very slow owing to an improvised HIV infection treatment option that brings the incidence of CMV retinitis down.

Competition in the CMV retinitis therapeutics market will remain weak in future. The current market is weak due to the low safety profile of the current marketed drugs. GlobalData anticipates that Hoffman La Roche will remain the leader in the CMV retinitis treatment drugs market until 2015. In 2015, the patent of its major drug for CMV retinitis, Valcyte, is due to expire. The current products display a low safety profile but a significantly high efficacy profile. These drugs are considered safer and more efficacious in the induction therapy, where there is a subsequent low unmet need of 25%. However, in the maintenance therapy the actual unmet need is higher considering the safety issues associated with the prolonged usage of the current drugs.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Cytomegalovirus-CMV-Infection-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

GlobalData revealed that the current competition in the CMV retinitis therapeutics market is weak, and the available treatment options are not completely successful in meeting market demand. The products currently in the CMV therapeutics market have displayed significantly high efficacy but the safety for the current drugs is low in overall. The chart below shows the safety and efficacy profiles of drugs in the induction therapy. The safety of drugs is much lower in case of prolonged use, which increases the overall
unmet need in the market.

GlobalData, the industry analysis specialist, has released its new report, “Cytomegalovirus (CMV) Retinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global CMV retinitis market and pipeline.The report identifies the key trends shaping and driving the global CMV Retinitis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter
the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CMV Retinitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Cytomegalovirus-CMV-Infection-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Rajesh Gunnam
GlobalData
London, EC4Y 0AN
+914066166782